At the heart of tumor development lies the capacity of cancerous tissues to remodel their surrounding microenvironment into an immunosuppressive fortress that thwarts effective antitumor immunity. Central to this remodeling are chemokines—small secreted proteins—and their receptors, which act as navigational cues orchestrating immune cell trafficking within the TME. This dynamic signaling network fosters the recruitment of immunosuppressive populations such as regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), while concurrently repelling or inducing exhaustion in cytotoxic effector cells including CD8+ T lymphocytes and natural killer (NK) cells.

Previous studies tended to focus narrowly on individual chemokine axes or select immune subsets, often overlooking the broader systemic interactions. In contrast, the present review offers a panoramic evaluation, positioning the chemokine system as a context-dependent, multidimensional regulatory apparatus. Tumor cells emit overlapping spatial gradients of multiple chemokines that act in concert to create a localized immunosuppressive niche. These gradients are precisely calibrated to enrich for suppressive immune cells while diminishing effector cell infiltration and function, effectively constructing a molecular barrier that insulates tumor cells from immune attack.

A particularly innovative contribution of the review is the proposed “3D” targeting framework—Decrease, Develop, and Dismantle—as a conceptual paradigm to guide next-generation immunotherapies aimed at reprogramming the TME. The “Decrease” strategy targets chemokine receptors such as CCR4, CCR8, CCR2, and CXCR2, which mediate the accumulation of Tregs, MDSCs, and TAMs, thereby reducing the tumor’s immunosuppressive cell burden. By antagonizing these receptors, therapeutic interventions may attenuate pro-tumorigenic inflammation and restore anti-tumor immunity.

The “Develop” approach focuses on potentiating the recruitment and activation of effector immune cells. Agonists targeting receptors like CXCR3, CXCR6, and XCR1 can enhance the homing, persistence, and cytotoxic capacity of effector T cells, NK cells, and conventional type 1 dendritic cells (cDC1), which are pivotal in antigen presentation and the initiation of robust immune responses. This arm of the strategy seeks to shift the TME from immunologically cold to hot, empowering immune cells to sustain durable tumor clearance.

“Dismantle” addresses structural and biochemical barriers imposed by the tumor niche itself. Targeting CXCR4 and disrupting its interaction with CXCL12, components critical for establishing stromal “immune-privileged” zones, has the potential to physically release trapped effector cells and break tumor-induced sequestration. This dismantling of immune exclusion zones holds promise for overcoming spatial blocks that have long hindered successful immunotherapy responses.

Despite the conceptual elegance and therapeutic promise of targeting chemokine pathways, the authors highlight formidable clinical challenges. Chief among these is the redundancy and adaptability inherent in the chemokine network. Tumors frequently compensate for blockade of a single receptor by upregulating alternative axes, blunting monotherapy efficacy. This necessitates precision medicine approaches that account for the exhaustive and dynamic redundancy within chemokine signaling circuits.

Toxicity profiles pose another hurdle, as demonstrated by anti-CCR4 agents, which inadvertently deplete beneficial CCR4-expressing central memory CD8+ T cells circulating outside the tumor. Such off-target effects underscore the need for selective targeting modalities to spare systemic immunity while remodeling the TME. The spatial and temporal heterogeneity of tumors further complicates intervention, demanding real-time, context-aware therapeutic adjustments.

Looking forward, Professor Yang and Professor Gao emphasize the importance of integrating cutting-edge technologies such as single-cell and spatial multi-omics to fully decode the chemokine communication landscape within the TME. Combining these insights with artificial intelligence-driven drug design could facilitate the development of highly specific agonists and antagonists tailored to individual tumor profiles. Furthermore, novel delivery platforms responsive to the tumor microenvironment may enable localized release, minimizing systemic exposure and toxicity.

Another promising avenue lies in preclinical models that accurately recapitulate patient tumor biology, including patient-derived organoids and organ-on-a-chip systems. These platforms offer unprecedented opportunities to validate complex combination therapies and to harness predictive insights for clinical translation. Such integrative, network-based approaches may ultimately unlock the long-sought clinical potential of chemokine-targeted immunotherapies.

This review captures a pivotal moment in oncology, where the convergence of molecular immunology, systems biology, and bioengineering is poised to revolutionize cancer therapy. By decoding and manipulating the chemokine-receptor networks shaping immune landscapes, scientists are paving the way for precision interventions that can dismantle tumor defenses and empower the immune system to achieve lasting remission and cure.

Subject of Research: Not applicable
Article Title: Chemokines and chemokine receptors: the key regulators of tumor microenvironment
News Publication Date: 8-May-2026
Web References: Not provided
References: DOI: 10.1007/s44466-026-00038-0
Image Credits: Professors Pengyuan Yang and Yanan Gao, Chinese Academy of Sciences, China

Keywords: tumor microenvironment, chemokines, chemokine receptors, immunosuppression, regulatory T cells, myeloid-derived suppressor cells, tumor-associated macrophages, immunotherapy, precision medicine, immune evasion, CXCR4, CCR4

TAMs and MDSCs derive primarily from circulating monocytes and bone marrow progenitors, yet recent evidence highlights the contribution of extramedullary hematopoiesis, especially from splenic hematopoietic stem and progenitor cells (HSPCs), to the continuous replenishment of these populations within tumors. This systemic mobilization is driven by tumor-secreted factors that induce emergency myelopoiesis, skewing progenitor differentiation toward immunosuppressive myeloid phenotypes. Once recruited, these cells colonize the tumor stroma, where chemokines such as CCL2, CXCL8, and colony-stimulating factor 1 (CSF-1) orchestrate their accumulation, survival, and proliferation through engagement of receptors like CCR2, CXCR2, and CSF-1R.

The metabolic landscape within the TME imposes significant constraints, including hypoxia and nutrient scarcity, compelling myeloid cells to undergo extensive metabolic reprogramming to sustain their functions. TAMs often upregulate glycolytic pathways, with lactate produced via enhanced glycolysis functioning as an immunomodulatory metabolite that stabilizes hypoxia-inducible factor 1-alpha (HIF-1α). This stabilization promotes epigenetic reprogramming through histone lactylation, driving the transcription of immunosuppressive genes such as interleukin-10 (IL-10) and arginase-1 (Arg1). Concurrently, shifts toward fatty acid oxidation (FAO) and amino acid metabolism are prevalent, with lipid accumulation in TAMs inducing chemokine secretion (e.g., CCL20) that attracts regulatory T cells (Tregs), further reinforcing immune evasion.

MDSCs exploit amino acid metabolism, particularly through the catabolism of arginine and tryptophan, to impair effector T cell function. Enzymes such as arginase and indoleamine 2,3-dioxygenase (IDO) contribute to the depletion of these critical nutrients, thus blunting anti-tumor immune responses. Moreover, MDSCs themselves rely heavily on glutamine and FAO pathways for energy and survival, processes intricately regulated by tumor-derived exosomes and cytokines, creating a feedback loop that perpetuates their suppressive capacity. The nuanced interplay between cellular metabolism and immunosuppressive signaling underscores metabolic reprogramming as a central axis dictating myeloid cell function in cancer.

Intracellular signaling cascades governing myeloid cell biology in the TME include activation of transcription factors such as signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB). These pathways are potentiated under hypoxic and metabolic stress conditions, augmenting myeloid survival and facilitating a phenotype conducive to tumor promotion. Additionally, autophagy modulates the cellular homeostasis and plasticity of TAMs and MDSCs, supporting their adaptation to hostile microenvironmental niches. The integration of these diverse signals ensures the persistence and expansion of myeloid populations that subvert immune surveillance.

Therapeutic efforts to mitigate the pro-tumoral impact of myeloid cells have intensified, focusing on strategies to disrupt recruitment, survival, and metabolic dependencies. Clinical trials investigating CSF-1R inhibitors aim to curtail TAM infiltration, while CCR2 and CXCR2 blockade targets monocyte and MDSC chemotaxis. Metabolic interventions targeting rate-limiting enzymes, such as 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) in glycolysis and carnitine palmitoyltransferase 1A (CPT1A) in FAO, hold promise in reprogramming myeloid phenotypes toward less suppressive states. Concurrent inhibition of arginase and IDO attempts to preserve amino acid availability for effector lymphocytes. However, the clinical translation of such approaches is challenged by compensatory immune mechanisms including polymorphonuclear MDSC infiltration and Treg expansion, highlighting the need for combinatorial and precision therapies.

Advancements in single-cell transcriptomics and spatial proteomics have revolutionized the dissection of myeloid heterogeneity within the TME. Distinct subsets—the likes of TREM2-positive TAMs and PD-L1-expressing macrophages—demonstrate divergent functional roles influenced by tumor type, tissue localization, and metabolic milieu. Unexpectedly, PD-L1+ macrophages have been associated with improved patient prognosis in hepatocellular carcinoma, challenging their traditional categorization as solely immunosuppressive. Similarly, lipid-associated macrophage subsets identified in aggressive triple-negative breast cancer have been implicated in resistance to immune checkpoint blockade, underscoring the heterogeneity and adaptability of these cells.

Explorations into the interplay between myeloid cells and other immune and stromal constituents reveal complex ecosystems driving tumor fate. Interactions with cancer-associated fibroblasts, neutrophils, and B cells create networks that can either facilitate or restrain tumor progression. The conceptual framework of “onco-spheres” envisions tumors as multipartite ecosystems with intricate crosstalk between local and systemic immunity, suggesting that therapeutic success depends on addressing these multifactorial interactions. Modulation of cholesterol metabolism and epigenetic regulators represents emergent avenues to recalibrate myeloid function, potentially enhancing immune responsiveness.

Beyond conventional therapeutic pipelines, repurposing existing drugs such as statins and glutamine antagonists to target metabolic vulnerabilities in myeloid cells offers an exciting translational prospect. β-glucan-like agents that “train” innate immunity indicate a novel paradigm, wherein myeloid cells are reeducated to mount enhanced anti-tumor responses. Such approaches underscore a shift from mere depletion to functional reprogramming of the myeloid compartment, aiming to restore immune equilibrium within the TME.

Addressing therapeutic resistance will require integrated strategies that simultaneously dismantle myeloid cell-mediated immune evasion and potentiate T cell efficacy. This necessitates an expanded focus on transcriptional and metabolic networks that govern cellular plasticity and intercellular signaling. Employing multi-omics integration alongside functional validation will be pivotal in identifying actionable targets that discriminate between pro- and anti-tumor myeloid subsets. Precision immunomodulation may ultimately transform the therapeutic landscape by turning once-pro-cancer myeloid cells into potent allies against malignancy.

The rapidly evolving understanding of myeloid cell biology in oncology heralds a new era of immunotherapy. By unraveling the complex metabolic and signaling circuits underpinning their diverse phenotypes, researchers can systematically exploit these vulnerabilities to reverse immune suppression, inhibit metastasis, and enhance durable responses. The convergence of experimental and computational methodologies promises to deliver personalized interventions that modulate the TME with unprecedented precision, marking myeloid cells not as mere bystanders but as linchpins in the fight against cancer.

Subject of Research: Not applicable
Article Title: Myeloid cells: key players in tumor microenvironments
News Publication Date: 5-Mar-2025
Web References: http://dx.doi.org/10.1007/s11684-025-1124-8
Image Credits: Qiaomin Hua, Zhixiong Li, Yulan Weng, Yan Wu, Limin Zheng
Keywords: Health and medicine